These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33506057)

  • 1. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Responsiveness of Lymph Nodes to Preoperative Chemoradiotherapy in Patients With Rectal Cancer on Prognosis After Radical Resection.
    Lee HG; Kim SJ; Park IJ; Hong SM; Lim SB; Lee JB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2019 Jun; 18(2):e191-e199. PubMed ID: 31014994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
    Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Extranodal Extension in Rectal Cancer Patients Undergoing Radical Resection After Preoperative Chemoradiotherapy.
    Kim YI; Cho H; Kim CW; Park Y; Kim J; Ro JS; Lee JL; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2021 Mar; 20(1):e35-e42. PubMed ID: 33191166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
    Tian YF; Chen TJ; Lin CY; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Shiue YL; Huang HY; Pan HY; Li CF; Chen SH
    Tumour Biol; 2013 Apr; 34(2):1107-17. PubMed ID: 23328995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 7. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
    Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
    Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer.
    Pucci S; Polidoro C; Joubert A; Mastrangeli F; Tolu B; Benassi M; Fiaschetti V; Greco L; Miceli R; Floris R; Novelli G; Orlandi A; Santoni R
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):381-388. PubMed ID: 28068245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
    Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
    Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
    Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profile is associated with chemoradiation resistance in rectal cancer.
    Gantt GA; Chen Y; Dejulius K; Mace AG; Barnholtz-Sloan J; Kalady MF
    Colorectal Dis; 2014 Jan; 16(1):57-66. PubMed ID: 24034224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
    Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
    Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
    Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
    Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
    Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
    Casado E; Garcia VM; Sánchez JJ; Gómez Del Pulgar MT; Feliu J; Maurel J; Castelo B; Moreno Rubio J; López RA; García-Cabezas MÁ; Burgos E; de Castro J; Belda-Iniesta C; López-Gómez M; Gómez-Raposo C; Zambrana F; Sereno M; Fernández-Martos C; Vázquez P; Lacal JC; González-Barón M; Cejas P
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1151-8. PubMed ID: 22516806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy.
    Park IJ; Yu CS; Lim SB; Yoon YS; Kim CW; Kim TW; Kim JH; Kim JC
    World J Gastroenterol; 2015 Mar; 21(11):3274-81. PubMed ID: 25805934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients.
    Agostini M; Zangrando A; Pastrello C; D'Angelo E; Romano G; Giovannoni R; Giordan M; Maretto I; Bedin C; Zanon C; Digito M; Esposito G; Mescoli C; Lavitrano M; Rizzolio F; Jurisica I; Giordano A; Pucciarelli S; Nitti D
    Cancer Biol Ther; 2015; 16(8):1160-71. PubMed ID: 26023803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.